سعر ماجنيفيست 468.01مجم/مل 20مل حقن وريدي 2024

Magnevist gadopentetate dimeglumine 469.01 mg/ml solution for intravenous injection, 20 ml, gadolinium-based contrast agent for MRI (Bayer; listed in Egypt).

• MRI of the central nervous system (brain, spine and associated tissues) to visualise lesions with abnormal vascularityPopulation: Adults and children 2 years and olderU.S. Food and Drug Administration (Drugs@FDA)
• MRI of extracranial/extraspinal tissues of the head and neckPopulation: Adults and children 2 years and olderU.S. Food and Drug Administration (Drugs@FDA)
• MRI of the body to visualise lesions with abnormal vascularityPopulation: Adults and children 2 years and olderU.S. Food and Drug Administration (Drugs@FDA)

• Most common (>= 1%): headache (4.8%), nausea (2.7%), injection site coldness (2.3%) and dizziness (1%).International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Postmarketing: anaphylactic shock and laryngeal oedema, cardiac/respiratory arrest, nephrogenic systemic fibrosis, acute renal failure, injection site skin/soft tissue necrosis, thrombophlebitis, arrhythmia, coma, hearing impairment and gadolinium-associated plaques; most frequently reported were nausea, vomiting, urticaria and rash.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m2).International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Acute kidney injury.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• History of severe hypersensitivity reactions to gadopentetate dimeglumine.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• Boxed warning - nephrogenic systemic fibrosis (NSF): gadolinium-based contrast agents increase NSF risk in patients with impaired elimination; avoid unless the diagnostic information is essential; screen for acute kidney injury and estimate GFR in patients at risk (e.g. age > 60, hypertension, diabetes); do not exceed the recommended dose and allow time for elimination before re-administration.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Hypersensitivity: anaphylactic/anaphylactoid reactions, rarely fatal, can occur; risk is higher with prior contrast reactions, asthma or allergic disorders; administer where resuscitation is immediately available and observe patients during and for several hours after injection.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Gadolinium retention: gadolinium is retained for months or years in bone, brain, skin and other organs; linear agents such as Magnevist cause more retention than macrocyclic agents; consider retention characteristics in patients needing multiple doses, pregnant women, children and patients with inflammatory conditions.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• GBCAs cross the placenta and cause fetal exposure and gadolinium retention; human data are limited and inconclusive. Use Magnevist in pregnancy only if imaging is essential and cannot be delayed.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)
• Limited reports suggest a breastfed infant would receive an oral dose of 0.001-0.04% of the maternal dose, with limited GI absorption; no data on effects on the infant or milk production; weigh benefits of breastfeeding against the mother's need.International label, same formulation · U.S. Food and Drug Administration (Drugs@FDA)

• Gadopentetate dimeglumine: Paramagnetic agent: in a magnetic field it shortens T1 (and T2) relaxation times of nearby water protons, increasing signal intensity where it accumulates, e.g. in lesions with a disrupted blood-brain barrier or abnormal vascularity (US label).